In this blog we recap our Early Detection & Screening (ED&S) Working Group’s summer seminar “Performance with Purpose: Metrics that Inform Clinical and Public Health Decisions,” which took place virtually on August 20 at 11:00 AM ET.

Featured speaker:

Peter Sasieni, PhD - Professor of Cancer Epidemiology and joint lead of the Centre for Cancer Screening, Prevention and Early Diagnosis

Following his talk, Dr. Sasieni was joined by two exceptional panelists for a dynamic discussion:

Donna Roscoe, PhD - Consultant and former Acting Director, Division of Molecular Genetics and Pathology (DMGP) in the Office of In Vitro Diagnostics at CDRH

Jody Hoyos, MHA - CEO of the Prevent Cancer Foundation

At the 2024 annual meeting of the American Association for Cancer Research (AACR), BLOODPAC’s Early Detection and Screening Working Group (ED&S WG) hosted a session focusing on cancer risk and risk assessment for liquid biopsy-based single- and multi-cancer screening.

In this article, we explore the identification, characterization, analysis, and clinical applications of circulating tumor cells in blood-based liquid biopsy for cancer management.

Any cancer diagnosis is devastating, but the discovery of a brain tumor comes with a unique set of challenges for both patient and doctor. In this article, we discuss the potential role of liquid biopsy for management of brain cancer, current research in this space, and remaining questions in the field.